BioCentury
ARTICLE | Company News

Medicines Co. gains on twin approvals

May 2, 2015 12:50 AM UTC

The Medicines Co. (NASDAQ:MDCO) announced its second approval of a therapy within 24 hours late Thursday, when it said the agency approved Ionsys, a transdermal fentanyl patch, to manage acute post-operative pain in hospitalized adults. Earlier in the day, FDA had approved Raplixa, a dry powder topical fibrin sealant composed of fibrinogen and thrombin previously known as FibroCaps, to treat mild to moderate surgical bleeding.

The Medicines Co. gained both therapies through acquisitions. In 2013, it acquired ProFibrix B.V., which developed Raplixa. The previous year, it bought Incline Therapeutics Inc., which developed Ionsys (see BioCentury Extra, Aug. 5, 2013 and BioCentury Extra, Dec. 12, 2012). ...